Image source: Shutterstock

Highlights

  • Neuren shares soar 18% after US FDA clears Phase 3 trial for Phelan-McDermid syndrome (PMS).

  • The Phase 3 trial builds on Phase 2 results where 89% of patients showed clinical improvement.

  • With no need for additional capital, the company is poised to begin the pivotal trial mid-2025.

Shares of Neuren Pharmaceuticals Ltd (ASX:NEU) surged 18% to AU$10.83 in morning trade, marking one of the biotech sector's performances to kick off the week. The sharp rally follows a significant regulatory milestone that could bring the company closer to launching a world-first treatment for a rare neurological disorder.

Investor optimism was sparked by Neuren’s announcement that the U.S. Food and Drug Administration (FDA) has given the green light for its Phase 3 trial of NNZ-2591, a drug candidate targeting Phelan-McDermid syndrome (PMS) — a rare and currently untreatable genetic condition.

The disorder is caused by deletions or mutations in the SHANK3 gene and is characterised by severe developmental delays, absent speech, autism-like symptoms, epilepsy, and significant quality-of-life impairments for both patients and caregivers. 

Promising Early Results, Regulatory Confidence

The planned placebo-controlled Phase 3 trial will build on Phase 2 data, where 16 of 18 children showed improvements in receptive communication and overall symptom change. These outcomes were described by the company as not only statistically significant but clinically meaningful.

Importantly, the upcoming trial’s design — including its co-primary endpoints and evaluation tools — has already received alignment from the FDA, reducing regulatory uncertainty going forward. The endpoints include assessments of receptive communication and global clinical impression of change, both validated during the Phase 2 trial.

Well-Funded and Ready for Execution

One of the key takeaways for investors is that Neuren does not require additional capital to proceed. This financial stability gives the company a clear runway to launch the trial in mid-2025, a rare advantage in the cash-intensive biotech sector.

Management noted that reaching this point marks a critical inflection in the company’s journey and could bring hope to families impacted by PMS.

“This is a vital step forward in our mission to develop a world-first treatment for a devastating and underserved condition,” the company stated in its release.